How many stocks are there of bioXXmed?
The current number of stocks of bioXXmed is 5.14 M undefined.
bioXXmed Stocks 2024
bioXXmed Stocks
5.14 M
bioXXmed Dividend yield
Ticker
T5O.DE
ISIN
DE000A0KFRJ1
WKN
A0KFRJ
In 2024, bioXXmed had 5.14 M outstanding stocks, a 0% change from the 5.14 M stocks in the previous year.
The bioXXmed Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2025e | 5.14 |
| 2024e | 5.14 |
| 2023e | 5.14 |
| 2022 | 5.14 |
| 2021 | 4.15 |
| 2020 | 4.15 |
| 2019 | 3.77 |
| 2018 | 2.77 |
| 2017 | 2.18 |
| 2016 | 2.06 |
| 2015 | 2.05 |
| 2013 | 1.87 |
| 2012 | 1.72 |
| 2011 | 1.68 |
| 2010 | 1.37 |
| 2009 | 1.37 |
| 2008 | 1.28 |
| 2007 | 1.28 |
| 2006 | 1.16 |
| 2005 | 1.16 |
| 2004 | 1.16 |
| 2003 | 1.16 |
| 2002 | 1.16 |
bioXXmed Aktienanalyse
What does bioXXmed do?
CytoTools AG is a German biotechnology company based in Darmstadt. It was founded in 2000 and has been listed on the Frankfurt Stock Exchange since 2006. The company focuses on the development of innovative therapies for diseases that have been difficult or impossible to treat so far. CytoTools relies on the use of active substances developed based on endogenous (body's own) molecules. A particular focus is on the research and development of active substances for the treatment of diseases based on inflammatory processes. CytoTools works closely with international research and development partners in this area. CytoTools' business model is based on the development and marketing of products based on innovative technologies and active substances. As a biotechnology company, it specializes in the development of patent-protected products and pursues a scalable business model. The company is divided into various divisions. In the "Pharmaceuticals" division, CytoTools develops innovative active substances and drugs for the treatment of diseases such as inflammatory diseases, cancer, or diabetes. An example of this is the active substance DermaPro, which can be used to treat chronic wounds. In the "Medical Devices" division, CytoTools develops medical devices for the diagnosis and therapy of diseases. An example of this is the CytoSorb system, which is used for extracorporeal blood detoxification and thus supports the treatment of severe infectious and inflammatory diseases. The third division of CytoTools is "Diagnostics". Here, the company develops innovative diagnostic tools for early detection of diseases. An example of this is the biomarker-based rapid test DermaPro Inflammation Score, which allows for a quick and reliable assessment of the inflammatory state of wounds. CytoTools has a strong network of partners and cooperation partners. The most important partners include institutions such as Kiel University, Flensburg University, or the Institute of Molecular Biotechnology in Jena. In addition, CytoTools works closely with international partners from the pharmaceutical industry. Overall, CytoTools is an innovative and rapidly growing biotechnology company specializing in the development of patent-protected products and technologies for the treatment of severe and previously incurable diseases. With its strong network of research and development partners and a wide range of products, the company is well-positioned to continue growing and develop new therapy concepts in the future. bioXXmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating bioXXmed's Shares Outstanding
bioXXmed's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in bioXXmed’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding bioXXmed’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in bioXXmed’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about bioXXmed Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of bioXXmed are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of bioXXmed evolved in recent years?
The number of shares of bioXXmed has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. bioXXmed as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of bioXXmed?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does bioXXmed pay?
Over the past 12 months, bioXXmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, bioXXmed is expected to pay a dividend of 0 EUR.
What is the dividend yield of bioXXmed?
The current dividend yield of bioXXmed is .
When does bioXXmed pay dividends?
bioXXmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of bioXXmed?
bioXXmed paid dividends every year for the past 0 years.
What is the dividend of bioXXmed?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is bioXXmed located?
bioXXmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von bioXXmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of bioXXmed from 5/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/26/2024.
When did bioXXmed pay the last dividend?
The last dividend was paid out on 5/26/2024.
What was the dividend of bioXXmed in the year 2023?
In the year 2023, bioXXmed distributed 0 EUR as dividends.
In which currency does bioXXmed pay out the dividend?
The dividends of bioXXmed are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von bioXXmed
Our stock analysis for bioXXmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of bioXXmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
